8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

____________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

December 22, 2007

Date of Report (Date of earliest event reported)

___________________________________________________________

Non-Invasive Monitoring Systems, Inc.

(Exact Name of Registrant as Specified in Charter)

___________________________________________________________

Florida	0-13176	59-2007840
(State of Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

IVAX Building

4400 Biscayne Boulevard 6^th Floor

Miami, Florida 33137

(Address of principal executive offices) (Zip Code)

(305)-861-0075

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On December 27, 2007, Non-Invasive Monitoring Systems, Inc. (the “Company”) issued a press release announcing that Steven B. Mrha has been appointed Chief Operating Officer of the Company beginning on January 14, 2008. A copy of the foregoing press release is furnished as Exhibit 99.1 to this Form 8-K.

Recently, Mr. Mrha served as Vice President of Sales and Marketing for IVX Animal Health, a member of the TEVA Group, based in St. Joseph, MO. In 2005, IVX Animal Health was established through the acquisition of Phoenix Scientific, Inc. by IVAX Corporation and its merger with IVAX's animal health division, DVM Pharmaceuticals, Inc. Prior to the merger, Mr. Mrha held the position of Vice President of Sales and Marketing for DVM Pharmaceuticals. He was responsible for developing and implementing the company’s core strategy and managing its execution. With his primary supervision of a nationwide sales force, a dynamic marketing department and reliable customer service department, DVM Pharmaceuticals gross revenue doubled in a six year period. He was also instrumental in both business and product development for DVM and in 1999 and 2002, he was honored with DVM Pharmaceuticals Award of Excellence representing outstanding performance towards the growth and future of the company. Following the merger with IVAX, he successfully led the commercial operations of the largest generic pharmaceutical company and premier branded dermatological/nutraceutical company in the animal health industry.

Mr. Mrha’s employment with the Company is “at will” and is governed by a offer letter dated December 21, 2007 and executed on December 22, 2007 (the “Agreement”). A copy of the Agreement is furnished as Exhibit 10.1 to this 8-K. Pursuant to the Agreement, Mr. Mrha was offered a salary of $255,730.00. Mr. Mrha was also offered, subject to approval by the Company’s Board of Directors (the “Board”), (a) an option to purchase 125,000 shares of the Company’s common stock at a strike price equal to the fair market value of the Company’s common stock on the date Mr. Mrha’s employment with the Company commences, which grant will be vested upon the commencement of Mr. Mrha’s employment; and (b) an option to purchase 100,000 shares of the Company’s common stock at a strike price equal to the fair market value of the Company’s common stock on the date Mr. Mrha’s employment with the Company commences, which grant will vest equally fifty percent (50%) per year on the first two anniversaries of the grant date of such option. Mr. Mrha will also be entitled to (i) participate in such benefit programs as are generally made available to other employees of the Company; (ii) reimbursement for COBRA premiums to maintain Mr. Mrha’s medical and dental insurance with his current employer until he is eligible to participate in the Company's medical and dental insurance plans; (iii) relocation expenses for up to six (6) months not to exceed $6,000; and (iv) four (4) weeks paid vacation each year.

Item 9.01 Financial Statements and Exhibits.

(c)    Exhibits

10.1 Offer Letter from Non-Invasive Monitoring Systems, Inc. to Steven B. Mrha dated December 21, 2007 and executed on December 22, 2007 detailing the terms of employment of Mr. Mrha.

99.1 Non-Invasive Monitoring Systems, Inc. Press Release dated December 27, 2007 (announcing the appointment of Steven B. Mrha as Chief Operating Officer).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NON-INVASIVE MONITORING SYSTEMS, INC.
By:	/s/ Marvin A Sackner, M.D.
	Name: Marvin A Sackner, M.D.
	Title: Chief Executive Officer, COBr

Dated:December 27, 2007

EX-10.1

EX-99.1

NIMS Announces Appointment of Steven B Mrha as Chief Operating Officer

MIAMI, FL - December 27, 2007 - Marvin A Sackner, M.D., Chief Executive Officer and Chairman Board of Directors, Non-Invasive Monitoring Systems, Inc. [NIMS] (NIMU.OB) announced the appointment of Steven B. Mrha as Chief Operating Officer of the Company to begin January 14, 2008.

Steven B. Mrha has been Vice President of Sales and Marketing for IVX Animal Health, a member of the TEVA Group, based in St. Joseph, MO. In 2005, IVX Animal Health was established through the acquisition of Phoenix Scientific, Inc. by IVAX Corporation and its merger with IVAX's animal health division, DVM Pharmaceuticals, Inc. Prior to the merger, Steven held the position of Vice President of Sales and Marketing for DVM Pharmaceuticals. He was responsible for developing and implementing the company core strategy and managing its execution. With his primary supervision of a nationwide sales force, a dynamic marketing department and reliable customer service department, DVM Pharmaceuticals gross revenue doubled in a six year period. Steven was also instrumental in both business and product development for DVM and in 1999 and 2002, he was honored with DVM Pharmaceuticals Award of Excellence representing outstanding performance towards the growth and future of the company. Following the merger with IVAX, Steven successfully led the commercial operations of the largest generic pharmaceutical company and premier branded dermatological/nutraceutical company in the animal health industry. In 2006, TEVA Corporation acquired IVAX resulting in the integration of IVX AH into TEVA.

Dr Sackner stated that “he is pleased that Steven Mrha has joined the Company as COO. He is a progressive, results oriented, award winning sales and marketing professional, with more than 20 years of sales management experience and a commitment to the belief that good team leadership and a hands-on approach to management bring increased standards and profits. He will be responsible for NIMS’ marketing and sales efforts for Exer-Rest’and Somno-Ease’ patented motorized motion platforms.”

Dr Sackner indicated that Exer-Rest’ will be available for marketing and sales in Canada, UK, Europe, South America, the Middle East and India in February 2008. Somno-Ease’ will be available in United States and those countries in April or May 2008. SingLin based in Taichung, Taiwan will distribute these products in the Far East.

The Exer-Rest’ motorized motion platform moves a supine individual repetitively head to foot about 140 times per minute. It has the appearance and functionality of either a cot or twin bed in standard and extra-long dimensions. Exer-Rest is currently being tested in a controlled pilot study for temporary relief of musculoskeletal pain associated with osteoarthritis of the hip(s) prior to the launch of a pivotal trial to be submitted to FDA for approval to market in the United States. Dr. Sackner added that “the Exer-Rest has the potential to serve as a non-invasive, drug-free, holistic alternative to drugs for the relief of the often debilitating pain of osteoarthritis.” Dr. Sackner further stated that “NIMS’ patented “Somno-Ease’,” is a motorized motion bed with gentle back and forth movements to soothe adults in the same way a mother soothes her baby as she pushes the baby carriage back and forth.” It also has a feedback mechanism to aid users in slow breathing maneuvers as a means to reduce stress.

Further information on the Company can be obtained on NIMS’ website at www.nims-us.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

Contact:

Non-Invasive Monitoring Systems, Inc., IVAX Building, 4400 Biscayne Blvd. 6^th Floor, Miami, FL 33137

Emerance Gummels, 305/861-0075

egummels@accelerationtherapeutics.com